EGFR T790M突变比例较高可能促成外显子19缺失患者较L858R患者获得更好生存
该研究纳入对EGFR酪氨酸激酶抑制剂获得性耐药且进展后接受活检的晚期EGFR突变NSCLC连续患者,分析耐药机制。Del19亚组T790M突变比例显著高于L858R亚组(50.4% vs 36.5%,p=0.043),T790M突变患者中位OS显著长于其他耐药机制组,Del19亚组中位OS也显著长于L858R亚组,但校正T790M基因型后EGFR突变亚型不再显著。
要点
- Del19亚组T790M突变比例显著高于L858R亚组(50.4% vs 36.5%,p=0.043)。
- T790M突变患者中位OS为36.0个月,显著长于MET阳性、组织学转化及KRAS/PIK3CA/ALK改变组。
- Del19亚组中位OS为33.3个月,L858R亚组为26.4个月(p=0.028)。
核心结论
- T790M突变患者观察到显著OS获益,提示较大比例的T790M突变可能促成Del19患者更好的生存。
研究设计与样本
- 研究纳入对EGFR酪氨酸激酶抑制剂获得性耐药且进展后接受活检的晚期EGFR突变NSCLC连续患者,分析T790M突变、MET扩增、组织学转化及KRAS、PIK3CA突变和ALK融合等耐药机制。
主要发现
- Del19亚组T790M突变比例显著高于L858R亚组(50.4% vs 36.5%,p=0.043)。
- 除T790M外,MET扩增和组织学转化等其他机制在两组间无差异。
- T790M突变患者中位OS为36.0个月(95%CI:30.9-41.2),显著长于MET阳性患者的26.5个月(95%CI:24.0-29.0)、组织学转化患者的19.7个月(95%CI:18.2-21.2)及KRAS/PIK3CA/ALK改变人群的23.0个月(95%CI:17.4-28.6)(p=0.021)。
- MET扩增亚组和组织学转化亚组的风险比分别为T790M阳性亚组的1.809倍和2.370倍。
- Del19亚组中位OS为33.3个月(95%CI:28.9-37.7),L858R亚组为26.4个月(95%CI:23.2-29.6)(p=0.028);但校正T790M基因型的多变量分析中,EGFR突变亚型不再显著。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Increasing evidence has demonstrated that exon 19 deletions (Del19) and L858R mutation in EGFR have different prognostic and predictive roles in NSCLC. We aimed to investigate whether these two mutations produced differences in mechanisms of resistance to EGFR tyrosine kinase inhibitors. METHODS: Consecutive patients with advanced EGFR-mutant NSCLC who acquired resistance to EGFR tyrosine kinase inhibitors and underwent postprogression biopsy were enrolled. Mechanisms including T790M mutation, mesenchymal-epithelial transition proto-oncogene (MET) amplification, and histological transformation, as well as KRAS, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene (PIK3CA) mutation, and anaplastic lymphoma receptor tyrosine kinase gene (ALK) fusion, were analyzed. RESULTS: The prevalence of T790M mutation was significantly higher in the Del19 subgroup than that in L858R subgroup (50.4% versus 36.5%, p = 0.043). Apart from this, there was no difference in other mechanisms including MET amplification and histological transformation. The median overall survival (OS) of patients with T790M mutation was 36.0 months (95% confidence interval [CI]: 30.9-41.2), which was significantly longer than the 26.5 months (95% CI: 24.0-29.0) in MET-positive patients, 19.7 months (95% CI: 18.2-21.2) in patients with histological transformation, and 23.0 months (95% CI: 17.4-28.6) in the KRAS/PIK3CA/ALK-altered population (p = 0.021). The hazard ratios of the MET-amplification subgroup and subgroup with histological transformation were 1.809-fold and 2.370-fold higher than that in T790M-positive subgroup. The median OS times were months 33.3 (95% CI: 28.9-37.7) in the Del19 subgroup and 26.4 months (95% CI: 23.2-29.6) in the L858R subgroup (p = 0.028). However, in multivariable analysis adjusted for T790M genotype, the EGFR mutation subtype was no longer found to be significant. CONCLUSIONS: Significant OS benefit was observed in patients with T790M mutation, suggesting that a larger proportion of T790M mutation might contribute to the better survival of patients with Del19.
引用
- Ke EE, Zhou Q, Zhang QY, et al. A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R. J Thorac Oncol. 2017. PMID: 28576746. doi:10.1016/j.jtho.2017.05.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。